Receptor selectivity from minimal backbone modification of a polypeptide agonist

Area of Science:

• Biochemistry
• Molecular Pharmacology
• Peptide Chemistry

Background:

• Human parathyroid hormone (PTH) and its N-terminal fragments activate two receptors, hPTHR1 and hPTHR2.
• A peptide containing the first 34 residues of PTH (PTH(1-34)) is a fully active, promiscuous agonist used clinically for osteoporosis treatment.

Purpose of the Study:

• To explore if backbone modification of a promiscuous peptide agonist can yield novel, receptor-selective agonists.
• To investigate the impact of β-amino acid substitutions on PTH receptor activation selectivity.

Main Methods:

• Synthesized a series of PTH(1-34) analogs with single β-amino acid replacements at the first eight positions (β-scan series).
• Assessed the potency of these analogs in cell-based assays for hPTHR1 and hPTHR2 activation.
• Identified highly selective agonists through systematic backbone modification.

Main Results:

• PTH(1-34) analogs with single backbone modifications exhibited varied potencies at hPTHR1 and hPTHR2.
• Two analogs with dual α→β replacements demonstrated high selectivity for either hPTHR1 or hPTHR2.
• The β-scan approach successfully identified receptor-selective peptide agonists.

Conclusions:

• Backbone modification of peptides represents a viable strategy for achieving activation selectivity among related receptors.
• Designing selective peptide agonists requires careful consideration of β-amino acid types (β2- vs. β3-residues) and their impact on side-chain positioning.